Metabolic syndrome in chronic schizophrenia: Cross-sectional hospital assessment of prolonged risperidone exposure.

Puntos clave

• This study aims to compare the risk of metabolic syndrome associated with long-term risperidone therapy versus olanzapine in patients with chronic schizophrenia.
• Conducted a cross-sectional assessment of patients exposed to risperidone for an extended period.
• Evaluated metabolic syndrome risk in comparison to olanzapine-treated patients.
• Recommended regular metabolic monitoring and interventions for high-risk individuals.
• Long-term risperidone therapy is linked to a lower risk of metabolic syndrome compared to olanzapine.
• Regular metabolic monitoring is advised for patients on risperidone, especially those at high risk.

Resumen